HOXA9 regulates miR-155 in hematopoietic cells

Yu-Long Hu, Stephen Fong, Corey Largman1,† and Wei-Fang Shen1,*

Department of Medicine, Department of Veterans Affairs Medical Center and University of California, San Francisco, CA 94143, USA

Received August 26, 2009; Revised April 15, 2010; Accepted April 19, 2010

ABSTRACT

HOXA9-mediated up-regulation of miR-155 was noted during an array-based analysis of microRNA expression in Hoxa9−/− bone marrow (BM) cells. HOXA9 induction of miR-155 was confirmed in these samples, as well as in wild-type versus Hoxa9-deficient marrow, using northern analysis and qRT–PCR. Infection of wild-type BM with HOXA9 expressing or GFP+ control virus further confirmed HOXA9-mediated regulation of miR-155. miR-155 expression paralleled Hoxa9 mRNA expression in fractionated BM progenitors, being highest in the stem cell enriched pools. HOXA9 capacity to induce myeloid colony formation was blunted in miR-155-deficient BM cells, indicating that miR-155 is a downstream mediator of HOXA9 function in blood cells. Pu.1, an important regulator of myelopoiesis, was identified as a putative downstream target for miR-155. Although miR-155 was shown to down-regulate the Pu.1 protein, HOXA9 did not appear to modulate Pu.1 expression in murine BM cells.

INTRODUCTION

Hoxa9 is expressed in numerous tissues during development including rib (1), limb (2), motor neuron progenitors (3), reproductive tract (4) and mammary gland (5). Hoxa9 is also expressed in normal adult bone marrow (BM) (6,7) and loss of Hoxa9 leads to multiple relatively mild defects in normal hematopoiesis (8–10). Hoxa9 is often up-regulated in acute myeloid leukemias (AMLs; 11,12), and in an analysis of 6817 genes, Hoxa9 was the most highly correlated with treatment failure in AML patients (13). Forced expression of HOXA9 in murine BM cells in culture results in immortalization of a myeloid progenitor cell (14,15), whereas transplantation of HOXA9-infected BM cells results in the eventual induction of AML (16). More recently, we have shown that HOXA9 regulates its DNA binding partner Meis1, and that deletion of one Meis1 allele in Hoxa9 deficient mice results in profound Pre/pro-B cell defects (17).

Despite the broad expression of Hoxa9 and other Hox genes, relatively little is known about how the HOX proteins function. An important advance was the discovery that many HOX proteins gain DNA binding specificity by forming complexes with the PBX (18,19), MEIS1 (20) and PREP1 (21) proteins. Although HOXA9 is capable of binding DNA alone (22), it forms cooperative DNA binding complexes with MEIS1 alone (20), as well as in a triple complex with PBX proteins (23,24). Despite these apparent advances and the publication of the HOXA9 transcriptome (25), only a few direct downstream targets for HOXA9 have been confirmed (26–28).

Following the early report that microRNAs (miRs) regulate aspects of hematopoietic lineage commitment (29), several studies have enumerated miR expression in normal BM fractions as well as in various leukemias (30,31). These studies have revealed that miRs play diverse roles in hematopoietic lineage decisions as well as in several types of leukemias. However, the regulation of miR expression in BM remains relatively poorly understood. Since the HOX proteins are thought to function as DNA binding transcription factors, as part of ongoing studies on the mechanism of action of the HOXA9 protein, we used an array analysis to identify downstream miR gene targets in murine BM cells. This analysis showed that HOXA9 up-regulates miR-155. HOXA9-mediated induction of myeloid colonies was impaired in miR-155-deficient mice, suggesting that miR-155 mediates some HOXA9 function(s) in BM cells. Although miR-155 was shown to down-regulate the hematopoietic modulator, Pu.1, HOXA9 did not alter Pu.1 protein levels, indicating that miR-155 functions in other pathways as a downstream mediator of HOXA9 action.

*To whom correspondence should be addressed. Tel: +1 415 476 6194; Fax: +1 415 514 3165; Email: wei-fang.shen@ucsf.edu

Present address:
Yu-Long Hu, Department of Neurological Surgery, University of California, 1450 3rd Street, San Francisco, CA 94143-0520, USA.

†Professor Emeritus UCSF School of Medicine (Deceased October 8, 2009).

© The Author(s) 2010. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
MATERIALS AND METHODS

Mice

Hoxa9-deficient mice have been described previously (10). miR-155-deficient mice were provided by Jackson Laboratories (Bar Harbor, MA, USA) and were re-derived from animals developed by Thai et al. (32).

Retroviral constructs and virus production

MSCV-HOXA9-1RES-EGFP (MIG-HOXA9) and MSCV-HOXA9NS-1RES-EGFP, encoding a DNA binding mutant (MIG-HOXA9NS) retroviral constructs were described previously (28). A hairpin expression construct for miR-155 was constructed by PCR amplification of the murine miR-155 sequence and 150 nt of 5' UTR. The PCR product was cloned into a retroviral vector (29). High-titer retrovirus was obtained by transfecting Phoenix amphotropic packaging cells using Metafectene transfection reagent (Biontex Laboratories, Munich, Germany). Virus-containing medium was harvested at 48 and 72 h after transfection, filtered through a 0.45-μm filter, and used without storing or freezing.

BM cell culture and retroviral transduction

BM cells from wild-type, Hoxa9-deficient mice, or miR-155-deficient animals were harvested 4 days after intraperitoneal injection with 150 mg/kg 5-fluorouracil and cultured in prestimulatory media consisting of Dulbecco's modified Eagle medium (DMEM) supplemented with 20% heat-inactivated FCS, 100 ng/ml recombinant murine (rm) SCF, 50 ng/ml rm IL-6 and 10 ng/ml rm IL-3 (StemCell Technologies, Vancouver, BC, Canada) for 48 h. Mouse BM cells were infected with retrovirus on two consecutive days by spinoculation in the presence of 5 μg/ml polybrene (Sigma, St Louis, MO, USA).

Analysis of miRs regulated by HOXA9 in murine BM cells

Total RNA from GFP+ Hoxa9−/− BM cells, infected with retrovirus expressing HOXA9-1RES-GFP, HOXA9NS-1RES-GFP or MIG vector alone, was harvested in lysis buffer (Ambion, #1931). Control and test miRs were labeled with Cy5 (Alexa Fluor 647, Invitrogen #A32757; Ambion labeling kit #1562) and hybridized to an Ambion miR array containing 397 unique miRs (Ambion #1566V1), according to the manufacturer's instructions. Microarrays were analyzed using GenePix software. miR analysis was performed in triplicate on two separate sets of infected BM samples. All values are means ± SD. A P < 0.05 denoted the presence of a statistically significant difference. Statistical analyses were performed using a two-tailed Student t-test.

Quantitative real-time RT–PCR and northern blotting analysis

GFP+ sorted BM cells from the different MIG-, MIG-HOXA9- or MIG-HOXA9NS-infected cells were resuspended in lysis buffer (#1931, Ambion). BM progenitors were sorted into long-term hematopoietic stem cells (HSCs), short-term HSCs and early progenitor pools through multichannel sorting (33). Equal amounts of total RNA were reverse transcribed to cDNA using Superscript II polymerase (Invitrogen). All PCR reactions were performed in an ABI Prism 7900HT sequence detection system (Applied Biosystems, Foster City, CA, USA) using FAM (Applied Biosystems) as described (7). qRT–PCR was used to measure murine miR-155 or U6 RNA levels by using Applied Biosystems kits (Applied Biosystems). Northern blotting was performed using antisense miR-155 or U6 probes. Statistical analyses were performed using Student’s t-test.

Fluorescence-activated cell sorting analysis

Fluorescence-activated cell sorting (FACS) sorting of primitive hematopoietic pools was performed following the methods developed in the Weissman laboratory (33). For the immunophenotyping of primitive marrow populations, the femurs and tibia of 15-day old mice were flushed with Hanks Balanced Salt Solution (Life Technologies, Bethesda, MD, USA) supplemented with 2% fetal calf serum (FCS) and 2 mM ethylenediaminetetraacetic acid. Then the BM cells were incubated with labeled antibodies for 30 min on ice, washed with cold-PBS twice and analyzed by FACS on Becton Dickinson FACScan using Cellquest software (Becton Dickinson, San Jose, CA, USA). Antibodies used for BM cell staining included phycoerythrin (PE)-conjugated Mac-1 (#55331), PE-Cy7-conjugated-Gr-1 (#552985), PE-conjugated B220 (#553089), fluorescein isothiocyanate (FITC)-conjugated IgM, PE-conjugated CD71 (#553267), PE-Cy7-conjugated Ter119 (#557853), FITC-conjugated CD41 (#553848), PE-conjugated CD61 (#553347), PE-conjugated Sca1 (#553108) and PE-Cy7-conjugated cKit (#558163), all of which were purchased from BD Pharmingen (BD Biosciences, San Diego, CA, USA).

Myeloid colony assays

CFU-myeloid colony assays (CFU-GM) were performed by culturing 2 × 10³ BM cells in M3434 medium (StemCell Technologies). Colonies were enumerated 7 days after plating (28).

RESULTS

HOXA9 regulates multiple miRs in BM cells

We previously described the cDNA transcriptome of the HOXA9 protein (25). The initial impetus for this project was to build on these data by describing the possible downstream miR targets regulated by HOXA9. A differential microarray analysis was performed using an Ambion chip containing 397 miR probes with small RNA from Hoxa9-deficient BM cells retrovirally infected with an MSCV vector expressing HOXA9 plus GFP or a GFP vector control. Figure 1A shows the relative expression levels of the HOXA9 and HOXA9-NS proteins expressed from the retroviral
vector, compared to the GFP control vector, in Hoxa9-deficient BM cells. HoxA9 significantly up-regulated 30 miRs but only down-regulated five miRs in murine BM cells (Table 1). Interestingly, 22 of the most highly expressed miRs in murine BM were not altered by HOXA9 expression. Among the putative miR targets regulated by HOXA9 identified in this analysis, we chose to focus on miR-155, which was up-regulated 1.56-fold ($P = 0.001$) in the array analysis, because of the published importance of this microRNA in hematopoiesis (34,35).

**miR-155 is up-regulated by HOXA9**

Northern blotting was initially used to confirm the array data for miR-155. Consistent with the array data, miR-155 was 2.7-fold higher in wild-type marrow than in Hoxa9-deficient BM cells (Figure 1B). Retroviral-mediated expression of HOXA9 in wild-type BM cells caused a 2.3-fold increase in miR-155, while a HOXA9-NS DNA binding mutant did not increase miR-155 significantly (Figure 1C). miR-155 is generated from the BIC non-coding transcript (34). In order to gain insight as to whether HOXA9 regulates miR-155 at the transcriptional level, we analyzed the effect of exogenous HOXA9 on BIC expression in BM cells. HOXA9 produced an ~10-fold increase in BIC mRNA, whereas the HOXA9-NS mutant was only able to minimally increase BIC expression (Figure 1D).

**miR-155 expression parallels Hoxa9 mRNA expression in BM progenitors and is highest in the stem cell pools**

Because miR-155 has been reported to play a regulatory role in hematopoiesis, we analyzed miR-155 expression in fractionated HSC and progenitor pools. Consistent with both a regulatory role for HOXA9 and a function for miR-155 in hematopoiesis, miR155 expression was much higher in the long- and short-term HSC pools than in the other progenitor pools (Figure 2A). We have recently reported that HOXA9 expression is also highest in the long-term and short term HSC pools (17). Thus, miR-155 expression closely parallels Hoxa9 mRNA expression during early hematopoiesis. It should be noted that the levels of HOXA9 protein are too low to be detected in the small numbers of BM stem cells that can be obtained from FACS sorting.

**miR-155 is downstream of Hoxa9 in murine BM cells**

To determine whether miR-155 mediates some of the biological properties of HOXA9, we used the fact that infection of murine BM cells with HOXA9 leads to a substantial expansion of myeloid progenitors as measured by colony formation (28). Retroviral-mediated expression of HOXA9 versus MIG control vector in wild-type murine BM compared to miR-155 ~/- BM was used to explore whether miR-155 was a downstream mediator of Hoxa9 (see Figure 1A for an example of HOXA9 expression generated using this system). HOXA9 induced a 2.6-fold increase in myeloid colony formation in wild-type BM cells (Figure 2B). In contrast, when HOXA9 was expressed in miR-155-deficient BM, there was a statistically significant decrease in induction of myeloid colonies ($P < 0.018$). These results demonstrate that the stimulatory effect of HOXA9 on colony growth was blunted in miR-155-deficient BM cells, strongly suggesting that at least some of the biological activity of HOXA9 in BM myeloid progenitor cells is mediated by miR-155.
miR-155 down-regulates Pu.1, but HOXA9 does not modulate Pu.1

After showing that HOXA9 up-regulated miR-155, and that miR-155 mediates at least some HOXA9 functionality, we used the available prediction programs to identify Pu.1 as a putative target for miR-155 (36). Pu.1 is an ETS family transcription factor that has been shown to play important regulatory roles in both normal myelopoiesis and leukemogenesis (37). To test the effects of miR-155 on Pu.1 expression, we generated a retroviral vector that expressed a miR-155 hairpin precursor. Although this vector produced an ~600-fold increase in miR-155 in 293T cells (data not shown), miR-155 expression increased only 8-fold following viral infection of wild-type BM cells (Figure 2C). Infection of either wild-type or Hoxa9-deficient BM cells with this miR-155 expression vector resulted in an ~50% decrease in Pu.1 protein (Figure 2D and E), a finding that has been reported by others since the inception of this work (38). These findings strongly suggested that HOXA9 might regulate Pu.1 via miR-155, and that this might be a significant window into understanding how the HOXA9 protein influences hematopoiesis. However, despite extensive analysis, we could not convincingly demonstrate a reproducible change in BM Pu.1 protein levels when HOXA9 was infected into either normal or Hoxa9-deficient cells (data not shown). We have concluded from these studies that the modulation of miR-155 by HOXA9 is not reflected by changes in Pu.1 expression.

**DISCUSSION**

Although the HOXA9 homeodomain protein appears to play important roles in numerous other tissues (1–5), we have focused in this study on its role(s) in normal hematopoiesis (29,39–43) and leukemia (40,44–46). In both blood and other tissues, despite the presence of a DNA binding domain and a presumption of transcriptional regulatory activity, the HOXA9 mechanism(s) of action remain relatively obscure. Although we have previously described the HOXA9 transcriptome (25), relatively few downstream targets have been authenticated. In this regard, we have previously reported that Pim1 is a direct downstream target (28). We also recently reported that HOXA9 can regulate its DNA binding partner Meis1, and that this process may be mediated by CREB1, which appears to be a direct HOXA9 target (17). Because of the dearth of well-understood mechanism to describe HOXA9 function, we undertook the current microarray-based survey of possible miR targets in BM cells.

### Table 1. miRs regulated by HOXA9 in BM cells

| miRNA                  | Expression levels | Fold change | P-value |
|------------------------|-------------------|-------------|---------|
| miRs down-regulated by Hoxa9 |                   |             |         |
| mir-15b                 | High              | 0.77 ± 0.12 | 0.02    |
| mir-23a                 | High              | 0.40 ± 0.06 | 0.01    |
| mir-25                  | High              | 0.55 ± 0.14 | 0.01    |
| mir-120                 | High              | 0.78 ± 0.02 | 0.01    |
| mir-342                 | High              | 0.48 ± 0.07 | 0.01    |
| miRs up-regulated by Hoxa9 |                  |             |         |
| mir-19b                 | High              | 1.53 ± 0.10 | 0.001   |
| mir-106b                | High              | 1.43 ± 0.38 | 0.03    |
| mir-147                 | High              | 2.46 ± 0.93 | 0.03    |
| **mir-155**             | High              | **1.56 ± 0.24** | **0.001** |
| mir-191                 | High              | 1.27 ± 0.18 | 0.014   |
| mir-297                 | High              | 2.21 ± 0.29 | 0.0002  |
| mir-122a                | Medium–high       | 2.67 ± 1.60 | 0.04    |
| mir-142-5p              | Medium            | 3.94 ± 2.30 | 0.05    |
| mir-302c-AS             | Medium            | 1.67 ± 0.34 | 0.003   |
| mir-124a-mm             | Medium–low        | 3.45 ± 2.60 | 0.05    |
| mir-142-3p              | Medium–low        | 3.98 ± 1.80 | 0.04    |
| mir-190                 | Medium–low        | 3.42 ± 0.11 | 0.01    |
| mir-211                 | Medium–low        | 3.50 ± 2.01 | 0.01    |
| mir-326                 | Medium–low        | 3.64 ± 2.10 | 0.03    |
| mir-525                 | Medium–low        | 5.07 ± 1.20 | 0.0002  |
| mir-34c                 | Low               | 3.68 ± 1.51 | 0.01    |
| mir-98                  | Low               | 3.31 ± 1.21 | 0.02    |
| mir-181c                | Low               | 2.76 ± 1.23 | 0.03    |
| mir-200c                | Low               | 2.21 ± 0.62 | 0.02    |
| mir-301                 | Low               | 3.25 ± 1.88 | 0.04    |
| mir-383                 | Low               | 3.85 ± 1.63 | 0.04    |
| mir-422b-mm             | Low               | 2.24 ± 1.15 | 0.04    |
| mir-518b                | Low               | 4.64 ± 0.79 | 0.0002  |
| mir-524                 | Low               | 3.58 ± 1.14 | 0.0004  |
| mir-527                 | Low               | 3.29 ± 0.18 | 0.003   |
| mir-30c-3p              | Very low          | 3.81 ± 1.58 | 0.02    |
| mir-143                 | Very low          | 3.56 ± 2.04 | 0.01    |
| mir-204                 | Very low          | 4.13 ± 2.14 | 0.01    |
| mir-485-5p              | Very low          | 2.96 ± 1.25 | 0.05    |
| mir-518f                | Very low          | 4.98 ± 1.58 | 0.004   |

Highly expressed miRs in BM, not regulated by Hoxa9 let-7a-7i Very high 0.99 ± 0.25 0.79
mir-21 Very high 1.03 ± 0.13 0.67
mir-93 Very high 0.97 ± 0.08 0.81
mir-103 Very high 0.96 ± 0.45 0.71
mir-106 Very high 0.96 ± 0.21 0.71
mir-107 Very high 1.00 ± 0.24 0.90
mir-210 Very high 1.04 ± 0.24 0.88
mir-223 Very high 1.03 ± 0.22 0.90
mir-494 Very high 1.00 ± 0.05 0.96
mir-22 High 1.03 ± 0.25 0.85
mir-23b High 0.97 ± 0.20 0.77
mir-26a,b High 1.00 ± 0.28 0.95
mir-29a High 1.01 ± 0.30 0.79
mir-30a-5p High 1.04 ± 0.18 0.91
mir-30c High 1.03 ± 0.38 0.92
mir-31 High 1.01 ± 0.35 0.87
mir-103b High 1.08 ± 0.28 0.75
mir-181a High 1.06 ± 0.26 0.68
mir-185 High 1.08 ± 0.34 0.79
mir-198 High 0.96 ± 0.48 0.94
mir-221 High 0.99 ± 0.10 0.88
mir-513 High 1.00 ± 0.45 0.84

Note: Bold values indicate significant changes. P-values were calculated using the paired Student’s t-test.
Given the limitations of the array technology, we chose to focus on miR-155 based primarily on published evidence of a reported role in hematopoiesis and/or leukemogenesis (34–35,38,47–49). One study reported that transgenic mice in which miR-155 is strongly expressed within the B-cell lineage develop lymphomas (48). Another reported that miR-155 was over-expressed in some AMLs and that forced expression of miR-155 in murine BM induced a myeloproliferative disease (35). Since forced Nup98-HOXA9 expression in murine BM also produces a myeloproliferative state (50), while HOXA9 alone appears to immortalize a promyelocytic progenitor (14), the observation that HOXA9 up-regulates miR-155, and that HOXA9 and miR-155 expression was correlated in hematopoietic stem cells, suggested that this process might partially explain HOXA9 mechanism of action. Our data, showing that a DNA binding mutant form of HOXA9 is incapable of up-regulating miR-155, further supports a working model for HOXA9 functioning as a transcription factor to regulate miR155 and subsequent down stream targets. In an attempt to discover a mechanism by which miR-155 might mediate the action of HOXA9, we used the existing prediction programs to identify Pu.1, an important regulatory protein for myelopoiesis and leukemogenesis (51), as a putative down-stream target of miR-155. Our data confirmed this
prediction by showing that forced expression of miR-155 does down-regulate Pu.1 protein. While this work was in progress, others also reported that Pu.1 is a direct target of miR-155 (38). Taken together, these data provided a strong working model for HOXA9 mechanism of action in hematopoiesis and leukemogenesis. We were therefore surprised that we were unable to demonstrate a regulatory role for HOXA9 on the Pu.1 protein. We posit that HOXA9 modulation of miR-155 regulates hematopoiesis by additional mechanistic pathways that remain to be described.

ACKNOWLEDGEMENT

This article is dedicated in loving memory of Dr C.L., who passed away during the preparation of the article.

FUNDING

Research Service of the Department of Veterans Affairs and by National Institutes of Health (Grant #CA80029). Funding for open access charge: Northern California Institute for Research and Education.

Conflict of interest statement. None declared.

REFERENCES

1. Chen,F. and Capecchi,M.R. (1997) Targeted mutations in hoxa-9 and hoxh-9 reveal synergistic interactions. Dev. Biol., 181, 186–196.
2. Fromental-Ramain,C., Warot,X., Lakkaraju,S., Favier,B., Haack,H., Birling,C., Dierich,A., Dolle,P. and Chambon,P. (1996) Specific and redundant functions of the paralogous Hoxa-9 and Hoxd-9 genes in forelimb and axial skeleton patterning. Development, 122, 461–472.
3. Dasen,J.S., Liu,J.P. and Jessell,T.M. (2003) Motor neuron columnar fate imposed by sequential phases of Hox-c activity. Nature, 425, 926–933.
4. Cheng,W., Liu,J., Yoshida,H., Rosen,D. and Naora,H. (2005) The Abd-B-like Hox homeodomain proteins can be subdivided by HOX genes that specify regional identity in the reproductive tract. Nat. Med., 11, 531–537.
5. Chen,F. and Capecchi,M.R. (1999) Paralogous mouse Hox genes, Hoxa9, Hoxb9, and Hoxd9, function together to control development of the mammary gland in response to pregnancy. Proc. Natl Acad. Sci. USA, 96, 541–546.
6. Kawagoe,H., Humphries,R.K., Blair,A., Sutherland,H.J. and Hogge,D.E. (1999) Expression of HOX genes, HOX cofactors, and MLL in phenotypically and functionally defined subpopulations of leukemic and normal hematopoietic cells. Leukemia, 13, 687–698.
7. Shen,W.F., Hu,Y.L., Utarwar,L., Passegue,E. and Largman,C. (2008) MicroRNA-126 regulates HOXA9 by binding to the homeobox. Mol. Cell. Biol., 28, 4609–4619.
8. Ison,D.J., Rozenfeld,S., Fong,S.T., Komuves,L., Largman,C. and Lawrence,H.J. (1998) Loss of function of the homeobox gene Hoxa-9 perturbs early T-cell development and induces apoptosis in primitive thymocytes. Blood, 92, 383–393.
9. Lawrence,H.J., Christensen,J., Fong,S., Hu,Y.L., Weissman,I., Sauvageau,G., Humphries,R.K. and Largman,C. (2005) Loss of expression of the Hoxa-9 homeobox gene impairs the proliferation and repopulating ability of hematopoietic stem cells. Blood, 106, 3988–3994.
10. Lawrence,H.J., Helgason,C.D., Sauvageau,G., Fong,S., Ison,D.J., Humphries,R.K. and Largman,C. (1997) Mice bearing a targeted interruption of the homeobox gene HOXA9 have defects in myeloid, erythroid, and lymphoid hematopoiesis. Blood, 89, 1922–1930.
11. Drabkin,H.A., Parsy,C., Ferguson,K., Guilhot,F., Lacotte,L., Roy,L., Zeng,C., Baron,A., Hunger,S.P., Varella-Garcia,M. et al. (2002) Quantitative HOX expression in chromosomally defined subsets of acute myelogenous leukemia. Leukemia, 16, 186–195.
12. Lawrence,H.J., Rozenfeld,S., Cruz,C., Matsukuma,K., Kwong,A., Komuves,L., Buchberg,A.M. and Largman,C. (1999) Frequent co-expression of the HOXA9 and MEIS1 homeobox genes in human myeloid leukemias. Leukemia, 13, 1993–1999.
13. Golub,T.R., Slonim,D.K., Tamayo,P., Huard,C., Gaasenbeek,M., Mesirov,J.P., Coller,H., Loh,M.L., Downing,J.R., Caligiuri,M.A. et al. (1999) Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science, 286, 531–537.
14. Calvo,K.R., Sykes,D.B., Pasillas,M. and Kamps,M.P. (2000) HOXa9 immortalizes a granulocyte-macrophage colony-stimulating factor-dependent promyelocyte capable of biphenotypic differentiation to neutrophils or macrophages, independent of enforced meis expression. Mol. Cell. Biol., 20, 3274–3285.
15. Fischbach,N.A., Rozenfeld,S., Shen,W., Fong,S., Chrobak,D., Ginzinger,D., Kogan,S.C.,Radhakrishnan,A., Le Beau,M.M., Largman,C. et al. (2005) HOXB6 overexpression in murine bone marrow immortalizes a myelomonocytic precursor in vitro and causes hematopoietic stem cell expansion and acute myeloid leukemia in vivo. Blood, 105, 1456–1466.
16. Kroon,E., Kros,J., Thorsteinsdottir,U., Baban,S., Buchberg,A.M. and Sauvageau,G. (1998) HOXa9 transforms primary bone marrow cells through specific collaboration with Meis1 but not Pbx1b. EMBO J., 17, 3714–3725.
17. Hu,Y.L., Fong,S., Ferrell,C., Largman,C. and Shen,W.F. (2009) HOXa9 modulates its oncogenic partner Meis1 to influence normal hematopoiesis. Mol. Cell. Biol., 29, 5181–5192.
18. Chang,C.-P., Shen,W.-F., Rozenfeld,S., Lawrence,H.J., Largman,C. and Cleary,M.L. (1995) Pbx proteins display hexametepide-dependent cooperative DNA binding with a subset of Hox proteins. Genes Dev., 9, 663–674.
19. Mann,R.S. and Affolter,M. (1998) Hox proteins meet more partners. Curr. Opin. Genet. Dev., 8, 423–429.
20. Shen,W.-F., Montgomery,J.C., Rozenfeld,S., Lawrence,H.J., Buchberg,A. and Largman,C. (1997) The Abd-B-like Hox proteins stabilize DNA binding by the Meis1 homeodomain proteins. Mol. Cell. Biol., 17, 6448–6458.
21. Berthelsen,J., Zappavigna,V., Ferretti,E., Malivio,F. and Blasi,F. (1998) The novel homeoprotein Prep1 modulates Pbx-Hox protein cooperativity. EMBO J., 17, 1444–1445.
22. Shen,W.-F., Rozenfeld,S., Lawrence,H.J. and Largman,C. (1997) The Abd-B-like Hox homeodomain proteins can be subdivided by the ability to form complexes with Pbx1a on a novel DNA target. J. Biol. Chem., 272, 8198–8206.
23. Shanmugam,K., Green,N.C., Rambaldi,I., Saragovi,H.U. and Featherstone,M.S. (1999) PXB and MEIS as non-DNA-binding partners in trimeric complexes with HOX proteins. Mol. Cell. Biol., 19, 3051–3061.
24. Dorsam,S.T., Ferrell,C.M., Dorsam,G.P., Derynck,M.K., Humphries,R.K., Roy,L., Zeng,C., Baron,A., Hunger,S.P., Varella-Garcia,M. et al. (2002) Quantitative HOX expression in chromosomally defined subsets of acute myelogenous leukemia. Leukemia, 16, 186–195.
25. Lawrence,H.J., Rozenfeld,S., Cruz,C., Matsukuma,K., Kwong,A., Komuves,L., Buchberg,A.M. and Largman,C. (1999) Frequent co-expression of the HOXA9 and MEIS1 homeobox genes in human myeloid leukemias. Leukemia, 13, 1993–1999.
26. Bei,L., Lu,Y. and Eklund,E.A. (2005) HOXA9 activates expression of the gene encoding gp91Phox during myeloid cell differentiation. Blood, 105, 3988–3994.
27. Bruhl,T., Urbich,C., Aicher,D., Acker-Palmer,A., Zeiher,A.M. and Dimmeler,S. (2004) Homeobox A9 transcriptionally regulates the EphB4 receptor to modulate endothelial cell migration and tube formation. Circ. Res., 94, 743–751.
28. Hu,Y.L., Passegue,E., Fong,S., Largman,C. and Lawrence,H.J. (2007) Evidence that the Pim1 kinase gene is a direct target of HOXA9. Blood, 109, 4732–4738.
30. Fabbri, M., Croce, C.M. and Calin, G.A. (2009) MicroRNAs in the ontogeny of leukemias and lymphomas. *Leuk. Lymphoma*, 50, 160–170.

31. Yendamuri, S. and Calin, G.A. (2009) The role of microRNA in human leukemia: a review. *Leukemia*, 23, 1257–1263.

32. Lewis, B.P., Shih, I.H., Jones-Rhoades, M.W., Bartel, D.P. and Burge, C.B. (2005) Prediction of mammalian microRNA targets. *Cell*, 120, 145–154.

33. Kastner, P. and Chan, S. (2008) PU.1 (SpI-1) and C/EBP epsilon regulates the ontogeny of hematopoietic cell lineages. *EMBO J.*, 27, 847–859.

34. Choong, M.L., Yang, H.H. and McNiece, I. (2007) MicroRNA expression profiling during human cord blood-derived CD34 cell erythropoiesis. *Exp. Hematol.*, 35, 551–564.

35. Smith, L.T., Hohaus, S., Gonzalez, D.A., Dziennis, S.E. and Tenen, D.G. (1996) PU.1 (SpI-1) and C/EBPβ regulate the granulocyte colony-stimulating factor receptor promoter in myeloid cells. *Blood*, 88, 1234–1247.

36. Costinean, S., Sandhu, S.K., Pedersen, I.M., Tili, E., Trotta, R., Perrotti, D., Ciarlariello, D., Neviani, P., Harb, J., Kauffman, L.R. et al. (2009) Ship and C/EBPβ are targeted by miR155 in B cells. *Mol. Cancer Res.*, 7, 1374–1382.

37. Sheedy, F.J. and O’Neill, L.A. (2008) Adding fuel to fire: microRNAs as a new class of mediators of inflammation. *Ann. Rheum. Dis.*, 67(Suppl 3), iii50–iii55.

38. Kroon, E., Thorstensdottir, U., Mayotte, N., Nakamura, T. and Sauvageau, G. (2001) UCP98HOX-A9 expression in hematopoietic stem cells induces chronic and acute myeloid leukemias in mice. *EMBO J.*, 20, 350–361.

39. Monticelli, S., Ansel, K.M., Xiao, C., Socci, N.D., Krichevsky, A.M., Thai, T.H., Rajewsky, N., Marks, D.S., Sander, C., Rajewsky, K. et al. (2005) MicroRNA profiling of the murine hematopoietic system. *Genome Biol.*, 6, R71.

40. Kuchenbauer, F., Morin, R.D., Argiropoulos, B., Petriv, O.I., Griffith, M., Heuser, M., Yung, E., Piper, J., Delaney, A., Prabhu, A.L. et al. (2008) In-depth characterization of the microRNA transcriptome in a leukemia progression model. *Genome Res.*, 18, 1787–1797.

41. Turner, M. and Vigorito, E. (2008) Regulation of B- and T-cell differentiation by a single microRNA. *Biochem. Soc. Trans.*, 36, 531–533.

42. Costinean, S., Sandhu, S.K., Pedersen, I.M., Tili, E., Trotta, R., Perrotti, D., Ciarlariello, D., Neviani, P., Harb, J., Kauffman, L.R. et al. (2009) Ship and C/EBPβ are targeted by miR155 in B cells. *Mol. Cancer Res.*, 7, 1374–1382.